These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27493187)

  • 1. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
    Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
    Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
    Carmony K; Lee W; Kim KB
    Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
    Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
    J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells.
    Skrott Z; Cvek B
    Mini Rev Med Chem; 2012 Oct; 12(12):1184-92. PubMed ID: 22931589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective synthesis of adamantylalanine and carboranylalanine and their incorporation into the proteasome inhibitor bortezomib.
    de Bruin G; Mock ED; Hoogendoorn S; van den Nieuwendijk AM; Mazurek J; van der Marel GA; Florea BI; Overkleeft HS
    Chem Commun (Camb); 2016 Mar; 52(21):4064-7. PubMed ID: 26894389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrochemical assay for 20S proteasome activity and inhibition with anti-cancer drugs.
    Henriques de Jesus CS; Chiorcea-Paquim AM; Barsan MM; Diculescu VC
    Talanta; 2019 Jul; 199():32-39. PubMed ID: 30952265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
    Li H; Bogyo M; da Fonseca PC
    FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib Inhibits Open Configurations of the 20S Proteasome.
    Henderson LW; Gautam AKS; Sharon EM; Johnson CR; Rommel NG; Anthony AJ; Russell DH; Jarrold MF; Matouschek A; Clemmer DE
    J Am Soc Mass Spectrom; 2024 Jun; 35(6):1063-1068. PubMed ID: 38748611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction.
    Santopolo S; Riccio A; Rossi A; Santoro MG
    Cell Mol Life Sci; 2021 Feb; 78(3):1113-1129. PubMed ID: 32607595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes.
    Zuo J; Bi C; Fan Y; Buac D; Nardon C; Daniel KG; Dou QP
    J Inorg Biochem; 2013 Jan; 118():83-93. PubMed ID: 23142973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
    Gallastegui N; Groll M
    Methods Mol Biol; 2012; 832():373-90. PubMed ID: 22350899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols.
    Glynn SJ; Gaffney KJ; Sainz MA; Louie SG; Petasis NA
    Org Biomol Chem; 2015 Apr; 13(13):3887-99. PubMed ID: 25669488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.